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Abbreviations
BSA  Bovine serum albumin
BDNF  Brain-derived neurotrophic factor
CNS  Central nervous system
CMZ  Ciliary marginal zone
DIV  Days in vitro
dpf  Days post fertilization
DMEM  Dulbecco’s modified Eagle’s medium
FGF  Fibroblast growth factor
NGFfluo  Fluorescently labelled NGF
FBS  Foetal bovine serum
GCL  Ganglion cell layer
GDNF  Glial cell-derived neurotrophic factor
hpf  Hours post fertilization
hpi  Hours post injection
INL  Inner nuclear layer
IVT  Intravitreal
MNP  Magnetic nanoparticle
NP  Nanoparticle
NGF  Nerve growth factor
NR  Neural retina
NT  Neurotrophin
PNS  Peripheral nervous system
Ph  Photoreceptor
PI  Polydispersion index
PLL  Poly-l-lysine
RGC  Retinal ganglion cell
ROS  Reactive oxygen species
RPE  Retinal pigment epithelium
RA  Retinoic acid
VEGF  Vascular endothelial growth factor
Abstract Glaucoma and other optic neuropathies are 
characterized by a loss of retinal ganglion cells (RGCs), 
a cell layer located in the posterior eye segment. Several 
preclinical studies demonstrate that neurotrophins (NTs) 
prevent RGC loss. However, NTs are rarely investigated 
in the clinic due to various issues, such as difficulties in 
reaching the retina, the very short half-life of NTs, and the 
need for multiple injections. We demonstrate that NTs can 
be conjugated to magnetic nanoparticles (MNPs), which act 
as smart drug carriers. This combines the advantages of the 
self-localization of the drug in the retina and drug protection 
from fast degradation. We tested the nerve growth factor 
and brain-derived neurotrophic factor by comparing the neu-
roprotection of free versus conjugated proteins in a model 
of RGC loss induced by oxidative stress. Histological data 
demonstrated that the conjugated proteins totally prevented 
RGC loss, in sharp contrast to the equivalent dose of free 
proteins, which had no effect. The overall data suggest that 
the nanoscale MNP-protein hybrid is an excellent tool in 
implementing ocular drug delivery strategies for neuropro-
tection and therapy.
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Introduction
Neurotrophins (NTs) are known to promote neuronal sur-
vival and regeneration in both the central (CNS) and periph-
eral nervous system (PNS) [1]. The exogenous delivery of 
NTs has also been proposed for the treatment of optic neu-
ropathies [2]. Optic neuropathies are a vast group of dis-
eases. Glaucoma is the most common, and is characterized 
by visual loss due to optic nerve dysfunction.
The loss of retinal ganglion cells (RGCs) is a common 
feature of neuropathies, irrespectively of the aetiology of the 
disease. Retinal ganglion cells are a type of neuron located 
near the inner surface of the retina, in the ganglion cell layer 
(GCL), which integrates visual information from photore-
ceptors (Ph) and projects it to the brain. The nerve growth 
factor (NGF) and brain-derived neurotrophic factor (BDNF) 
are members of the NT family, which have been shown to 
prevent damage to GCL. NGF promotes the survival and 
recovery of retinal ganglion cells [3, 4]. It has been demon-
strated that the injection of exogenous NGF protects retinal 
ganglion cells from degeneration and apoptosis in different 
experimental models of retinal detachment, diabetic retin-
opathy and glaucoma [5–7]. Clinical studies suggest that the 
administration of NGF eye drops improves all parameters 
of visual function in patients with advanced glaucoma [8]. 
Similarly, BDNF enhances the survival of GCL in vitro and 
in vivo [9–11]. BDNF also prevents the in vivo cell death of 
GCL induced by optic nerve lesions, providing therapeutic 
neuroprotection [12, 13].
The key limitation of NTs in the treatment of PNS and 
CNS diseases is their inability to cross the blood–brain bar-
rier. Similarly, the eye has its own barriers. It is composed 
of two segments enveloped by the cornea and sclera: the 
anterior segment, which includes the cornea, the aqueous 
humour and the iris, and the posterior segment, which con-
tains the lens, the vitreous humour, the neural retina (NR), 
the retinal pigment epithelium (RPE), and the choroid. The 
poor permeability of cornea/sclera and the blood retinal bar-
rier make the systemic administration of NTs ineffective in 
reaching the retina.
A variety of approaches associated with the delivery of 
NTs to the retina have been proposed for local administra-
tion, including direct delivery, viral gene therapy, and cell-
based therapy, which improve the development, survival, and 
function of retinal ganglion cells [14].  Renexus® (NT-501) is 
an intravitreal (IVT) implant encapsulating the human RPE 
cell line genetically modified to secrete the ciliary neuro-
trophic factor (CNTF). It is currently in phase 2 of a clinical 
trial for the treatment of glaucoma (NCT02862938), early-
stage retinitis pigmentosa (NCT01530659), and macular tel-
angiectasia (NCT03071965). However, the direct delivery 
of proteins through IVT injections is the safest, most effec-
tive and common approach tested to date. Repeated IVT 
injection of anti-vascular endothelial growth factor agents 
(bevacizumab, ranibizumab, or pegaptanib) has become a 
gold standard anti-angiogenic treatment in many clinics [15].
However, the real potential of direct IVT injection of NTs 
as neuroprotective/restorative drugs in ophthalmology, has 
yet to be proven and many limitations still prevent its appli-
cation in clinics. NTs have a very short half-life in vivo and 
unfavourable kinetics, with a very high initial peak of drug 
concentration at the time of administration, rapidly followed 
by a decline over time (minutes). Multiple IVT injections are 
thus required to obtain therapeutic efficacy, eliciting a con-
crete risk of cataracts, retinal ischemia and endophthalmitis 
[16]. Another serious problem related to multiple injections 
has been described by Chen and Weber, who showed that 
multiple applications of BDNF do not have an additive effect 
because the continuous application of BDNF intravitreally 
leads to the downregulation of its receptor [17].
To overcome problems of a short half-life, dosing and the 
undesirable effects of multiple injections, the incorporation 
of BDNF in a hyaluronic acid aqueous solution has been 
proposed [3]. The use of IVT injected nanoformulations has 
also been explored, such as the injection of basic fibroblast 
growth factor (FGF)-impregnated nanoparticles (NP) [4] 
or poly-lactic-co-glycolic acid (PLGA) microspheres con-
taining NTs [18]. A single IVT injection of the glial cell-
derived neurotrophic factor (GDNF) encapsulated in vitamin 
E/PLGA microspheres was found to protect RGCs in animal 
models of glaucoma for up to 11 weeks by providing the 
sustained controlled release of GDNF in a controlled fashion 
for up to 6 months [19, 20].
In previous studies, we demonstrated that magnetic nano-
particles (MNPs) could be used to bypass the limitations 
related to the IVT injection of free proteins [21, 22]. MNPs 
are largely used in biomedicine. They are biodegradable nan-
oparticles, which typically consist of a superparamagnetic 
central core of iron oxide surrounded by an organic coat. 
Several generations of MNPs have already been approved by 
the FDA for use on humans as contrast agents for magnetic 
resonance imaging or for the treatment of chronic anaemia 
[23].
We found that IVT-injected MNPs autonomously local-
ise themselves in the retina where they persist for at least 
3 weeks [21, 22]. In principle, MNP-mediated drug delivery 
could provide a therapeutically effective concentration of the 
carried molecule for weeks in the right location, thereby pre-
venting side effects in other tissues. In addition, the molecule 
localization mediated by MNPs could prevent mass losses 
due to molecule degradation or physiological elimination by 
the humour vitreous.
In this paper, we demonstrate that NGF and BDNF con-
jugation to MNPs increases their stability. The function-
alized particles are localized in the retina. We tested the 
neuroprotection of conjugated NTs, demonstrating that their 
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IVT administration totally prevents retinal ganglion cell loss 
induced by oxidative stress. Interestingly, we used NGF and 
BDNF concentrations that were tenfold lower than the effec-
tive dose proposed in the literature and, in agreement with 
the previous data, we found that free NTs had no neuropro-
tective effects, in sharp contrast to the conjugated NTs.
Materials and methods
Functionalization of MNPs
Commercial MNPs were used (FluidMAG-ARA 4115, 
Chemicell). According to the datasheet, MNPs have a mag-
netite core of iron oxide (50 nm in size) and an organic shell 
which exposes –COOH groups. The particles were func-
tionalized with NGF 2.5S (Alomone, N100) or fluorescently 
labelled NGF  (NGFfluo) or recombinant BDNF or bovine 
serum albumin (BSA, Sigma, A2153).  NGFfluo was produced 
as already described [24], by labelling 100 µg of NGF 2.5S 
with Alexa Fluor 488 (Life Science, A10235), according to 
the manufacturer’s instructions. Purification through a size 
exclusion resin enabled the uncoupled dye to be discarded. 
The degree of labelling was about 1.5 mol of dye per mole 
of protein, and the efficiency of the labelling process was 
about 90% (n = 3).
The functionalization of the particles was carried out 
using an MNP:protein ratio of 3.5:1 w/w. For NGF and 
 NGFfluo, we adopted a non-covalent approach as previously 
described [24–26]. Briefly, the MNP:protein suspension was 
incubated at 4 °C for 2 h with stirring. For BDNF and BSA, 
particles were covalently functionalized via EDC chemistry, 
according to a protocol that we optimized in previous stud-
ies with other proteins [22, 25, 26]. Briefly, particles were 
centrifuged (18,000g) and resuspended in 4% EDC (Sigma) 
water solution. After 10 min, the protein was added and 
mixed for 1 h at 4–8 °C. In both protocols, the unbounded 
protein was removed by centrifugation (18,000g) and by dis-
charging the supernatant (two washing steps).
The amount of protein bound to the surface of MNPs 
was calculated by subtraction, i.e., by measuring the protein 
concentration (Bradford assay) of the supernatant derived 
from the washing steps. The amount of magnetic nanopar-
ticles was quantified using the thiocyanate assay, according 
to a protocol we published previously [27]. Briefly, 3 µl of 
particle suspension was resuspended in 50 μl of a solution of 
6 M HCl: 65% v/v  HNO3 and incubated at 60 °C for 1 h. The 
sample was water diluted 1:10, an equal volume of 1.5 M 
KSCN was added, and absorbance recorded at 478 nm. The 
calibration curve was obtained with a known amount of 
MNPs (y = 0.055x, R2 = 1), where y is the absorbance at 
478 nm and x is the MNP concentration (mg/ml). The conju-
gated nanoparticles and the free proteins were stored in 20% 
glycerol at − 20 °C. The composition of MNP–NGF was 
9.50 ± 0.11 mg/ml of MNPs, 0.90 ± 0.01 mg/ml of NGF, 
20% glycerol (n = 4). The composition of MNP–NGFfluo 
was 14 ± 0.15 mg/ml of MNPs, 0.43 ± 0.19 mg/ml of NGF, 
20% glycerol (n = 4). The composition of MNP–BDNF was 
13.88 ± 0.24 mg/ml of MNPs, 1.03 ± 0.15 mg/ml of BDNF, 
20% glycerol (n = 4). The composition of MNP-BSA was 
11.76 ± 0.14 mg/ml of MNPs, 0.90 ± 0.13 mg/ml of BSA, 
20% of glycerol (n = 4).
The functionalized particles were characterized in terms 
of hydrodynamic size and Z potential by Delsa™NanoC 
(Beckman Coulter Fullerton, CA, USA).
Cell cultures
Rat pheochromocytoma PC12 cells obtained from the Amer-
ican Type Culture Collection (ATCC) were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) with 10% horse 
serum, 5% foetal bovine serum (FBS), 100 IU/ml penicillin, 
100 µg/ml streptomycin, and 2 mM l-glutamine. Cells were 
cultured in plastic coated with poly-l-lysine (PLL, Sigma, 
P1274) and maintained at 37 °C in a saturated humidity 
atmosphere of 95% air and 5%  CO2. For cell differentia-
tion, PC12 cells were incubated for 4 days in serum-reduced 
media (1% FBS), modified with MNP–NGF or free NGF 
(100 ng/ml). For Western blot (WB) analysis, PC12 cells 
were starved for 5 h in Optimem (Gibco) and incubated 
for 5 min in serum-reduced media unmodified (control) or 
modified with MNP–NGF or NGF (100 ng/ml). WB analysis 
was performed on protein extracts from PC12 cells using 
phospho-TrkA (Tyr490) antibody (Cell Signaling, 9141) and 
β-actin antibody (Sigma, A1978).
The human neuroblastoma SH-SY5Y cell line obtained 
from ATCC was cultured in DMEM/F12 medium with 10% 
FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin and 
2 mM l-glutamine. For cell differentiation, SH-SY5Y cells 
were incubated for 5 days in a cell growth medium modified 
with 10 µM retinoic acid (RA). Neurite networking was then 
induced by incubating cells for 5 days in DMEM unmodi-
fied (control) or modified with MNP–BDNF or free BDNF 
(100 ng/ml). Neurite networking was calculated by counting 
the number of interconnected neurites (i.e., neurites con-
nected with at least one other neurite) over the total number 
of neurites (n = 5, 250–300 neurite per replicate).
Stability in medium
Free or conjugated NGF was added to protease-rich medium 
(70% FBS, not inactivated) at a final concentration of 10 µg/
ml. The medium was incubated at 37 °C for 0, 4, 10 or 
14 days. Aliquots were collected at different time points 
and used to prepare the differentiation medium for inducing 
PC12 cell differentiation.
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Free or conjugated BDNF was added to DMEM at a final 
concentration of 100 ng/ml. The medium was incubated at 
4 °C for 0, 3 or 6 days. Aliquots from the different time 
points were used to induce network formation in RA-differ-
entiated SH-SY5Y cells.
After incubation, cells were fixed in 2% paraformalde-
hyde for 20 min and stained with 0.05% crystal violet.
Embryo preparation
Animal procedures were performed in strict compliance with 
protocols approved by the Italian Ministry of Public Health 
and of the local Ethical Committee of the University of Pisa 
(authorization 99/2012-A, 19.04.2012), in compliance with 
EU legislation (Directive 2010/63/EU). Zebrafish embryos 
(roy−/−; nacre−/− and AB) were obtained by natural mating 
and raised according to the ZFIN procedures (authorization 
1173/2015-PR). Before any injection, larvae were anesthe-
tized in 0.02% tricaine and embedded in 0.3% agarose.
Localization studies
Two nl containing 10 or 20 ng of MNPs or MNP–NGF or 
MNP–BDNF were microinjected into the left eye of a four-
day post-fertilization (dpf) larvae and fixed at 24 h post 
injection (hpi). Zebrafish larvae were fixed in 4% paraform-
aldehyde for 1 h, embedded in paraffin and sectioned (5 µm). 
The paraffin sections were stained by Prussian blue accord-
ing to the manufacturer’s instructions (Sigma-Aldrich, St. 
Louis, USA) after a treatment of pigment bleaching in 5% 
formamide-1% hydrogen peroxide in the presence of cold 
light. The number of events (presence of staining in NR and/
or RPE and/or choroid, Fig. S1) was counted and data were 
plotted after normalization.
In another experiment, 2  nl containing 10  ng of 
MNP–NGFfluo were microinjected into the left eye of 4 dpf 
larvae and fixed at 6 hpi. Sections were imaged in bright 
field and in FITC channel.
Each experiment was performed on at least 15 larvae per 
group.
Oxidative stress model
Two nl of  H2O2 (0, 0.25, 0.5 or 1 M) were injected into the 
left eye of 5 dpf larvae. After 2 or 4 or 8 or 24 hpi, larvae 
were fixed in 4% paraformaldehyde for 1 h, embedded in 
paraffin, and sectioned (5 µm). The paraffin sections were 
stained with the DeadEnd™ Fluorometric TUNEL System 
(Promega Corporation, USA) and Hoechst 33342 (Sigma-
Aldrich, St. Louis, USA) according to the manufacturer’s 
instructions. The number of TUNEL-positive cells in the 
layer of photoreceptors (Ph), the inner nuclear layer (INL), 
the ganglion cell layer (GCL) and the ciliary marginal zone 
(CMZ) was counted and normalized with respect to the total 
cell number (Hoechst stained nuclei) in Ph, INL, GCL and 
CMZ, respectively (Fig. S2). Each value was calculated as 
the mean of three sections. Each experiment was performed 
on at least 15 larvae per group.
Neuroprotection study
Two nl of free neutrophic factors or conjugated neutrophic 
factors or saline were microinjected into the left eye of 4 
dpf larvae. At 16 hpi, 2 nl of 1 M  H2O2 were injected into 
the same eye. Larvae injected with saline at 4 dpf but non-
microinjected with  H2O2 were used as negative controls. 
Eight hours later, zebrafish larvae were fixed, paraffin-
embedded, sectioned and stained with TUNEL. After stain-
ing, sections were bleached and stained for particles (Prus-
sian blue). Only embryos positive for particles were analysed 
as mentioned above. Each experiment was performed on at 
least 15 larvae per group.
Optokinetic response (OKR) assay
To test ocular tocixity, 2 nl of MNPs were microinjected into 
the left eye of 4 dpf larvae and non-injected larvae were used 
as controls. At 1 dpi, the OKR analysis was performed. For 
functional recovery analysis, 2 nl of free NTs or conjugated 
NTs or saline were microinjected into the left eye of 4 dpf 
larvae. At 16 hpi, 2 nl of 1 M  H2O2 were injected into the 
same eye. Eight hours later, 5–9 zebrafish larvae were placed 
in a 3.5 mm Petri dish and embedded in 3% methylcellu-
lose, with the dorsal side up around a small air bubble. The 
Petri dish was inserted inside the drum with black and white 
stripes rotating at ~ 6 rpm as described [28] and a video 
was recorded. For each larva, the number of saccades of 
the left eye per minute was recorded. Each experiment was 
performed on at least 10 larvae per group, n = 3.
Data plotting and statistics
Data were plotted and analysed using GraphPad Prism. Val-
ues were reported as the mean ± standard error of the mean. 
Significance was set at p ≤ 0.05. Statistical analyses were 
performed by ANOVA followed by Bonferroni correction or 
t test with Welch’s correction. * is p < 0.05, ** is p < 0.01, 
*** is p < 0.001.
Results
Physical characterization of MNP–NT
The size distribution of MNPs was characterized by 
dynamic light scattering (Table 1, Fig. S3). Particles had a 
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hydrodynamic size of 90.47 ± 2.88 nm and Polydispersity 
Index (PI) of 0.337 ± 0.022. MNPs exhibited a negative Z 
potential (− 38.72 ± 2.14 mV), due to their surface func-
tionalization with carboxylic groups.
For the synthesis of MNP–BDNF, we chemically linked 
the protein to MNPs. We found that the loading content 
was about 74 µg of BDNF per mg of MNPs. The hydrody-
namic size of MNP–BDNF was 273.07 ± 9.31 nm and the 
PI was 0.346 ± 0.009. The presence of BDNF on particle 
surfaces was further confirmed by Z potential measurement, 
which shifted from − 38.72 ± 2.14 mV for naked MNPs to 
− 0.04 ± 0.03 mV for MNP–BDNF (the isolectric point of 
BDNF is 9.99).
For the synthesis of MNP–NGF, NGF was physically 
loaded onto MNPs by exploiting electrostatic interac-
tions between the negatively charged MNP and the posi-
tively charged NGF (the isoelectric point of NGF 2.5S 
is 9.3). The loading content was about 95 µg of NGF per 
mg of MNPs. The hydrodynamic size of MNP–NGF was 
189.57 ± 5.91 nm and the PI was 0.328 ± 0.002. The pres-
ence of NGF on particle surfaces was confirmed by Z poten-
tial measurement, which shifted from − 38.72 ± 2.14 mV for 
naked MNPs to − 1.59 ± 0.21 mV for MNP–NGF.
Biological characterization of MNP–NT: 
biofunctionality and long‑term activity of conjugated 
versus free NTs
The next step was to demonstrate that the conjugation pro-
cess did not alter protein biofunctionality. We validated 
the ability of BDNF signalling to induce the neurite net-
work [29]. The human neuroblastoma cell line SH-SY5Y 
was differentiated in the presence of retinoic acid (RA). 
RA-differentiated cells showed an extensive neurite net-
work when incubated with BDNF or MNP–BDNF (100 ng/
ml), in contrast to BDNF-free incubation (Fig. 1a). In the 
BNDF-free sample, the population of interconnected neur-
ites (i.e., neurites connected with at least one other neurite) 
was about half (47.15 ± 3.86%). In contrast, in the BDNF 
and MNP–BDNF groups, most neurites were interconnected 
(89.57 ± 2.45 and 87.15 ± 0.642, respectively) and these 
values were not statistically different (p > 0.05). Similarly, 
we validated the ability of NGF to trigger PC12 differentia-
tion in a neuron-like phenotype. Functional analysis showed 
that PC12 cells incubated for 4 days in reduced medium 
modified with NGF or MNP–NGF (100 ng/ml) showed the 
same differentiated phenotype as long neurites (Fig. S4, 
 NGFDIV0 and MNP–NGFDIV0), in agreement with our previ-
ous observations [24–26]. Molecular analysis confirmed this 
result. PC12 cell extracts were analysed by Western blot to 
detect the endogenous levels of the receptor TrkA activated 
by NGF (i.e., phosphorylated at tyrosine 490), confirming 
that both NGF and MNP–NGF induce NGF receptor phos-
phorylation (Fig. 1C1).
The stability of the free and conjugated neurotrophic 
factors was examined in different conditions. BDNF (blood 
half-life is 0.92 ± 0.04 min [30]), was incubated in DMEM 
at 4–8 °C from DIV0 (freshly frozen) to DIV6. BDNF or 
MNP–BDNF samples were collected at different time points 
and tested for their ability to induce the neurite network in 
RA-differentiated SH-SY5Y cells. NGF (blood half-life is 
7.2 ± 0.3 min [30]) was incubated in protease-rich serum at 
37 °C from 0 (freshly frozen) to DIV14. NGF or MNP–NGF 
samples were collected at different time points and molecu-
lar and functional analyses were performed to test their abil-
ity to induce PC12 cell differentiation.
The results demonstrated that the conjugated neuro-
trophic factors were significantly more stable than the 
free factors. Figure 1b shows the number of intercon-
nected neurites in RA-differentiated SH-SY5Y cells incu-
bated with free or conjugated BDNF. Statistical analyses 
were performed by comparing groups with freshly fro-
zen samples (DIV0). We found a decrease in the activ-
ity of free BDNF over time, which reached statistical 
significance in the DIV6 sample. In contrast, no differ-
ences had been detected with conjugated BDNF by day 
six. Similarly, we observed that the bioactivity of free 
NGF quickly decreased over time, and cellular debris, 
which forms following cell death due to the lack of the 
cell differentiation stimulus mediated by NGF, was present 
in the cultures starting with DIV4 (Fig. 1D1). Cellular 
debris accumulated in the following time points (Fig. S4), 
until reaching complete cellular degeneration in cultures 
treated with NGF pre-incubated for 14 days (Fig. 1D2). In 
sharp contrast, in cultures treated with conjugated NGF 
DIV4-DIV14, PC12 cells exhibited long neurites without 
morphological differences from control cultures differenti-
ated with freshly frozen NGF or freshly frozen MNP–NGF 
(Fig. S4). Cellular debris or signs of degeneration were 
Table 1  Z potential, diameter 
and Polydispersion Index 
of naked and functionalized 
nanoparticles
Mean ± SEM. n = 3
Z potential (mV) Diameter (nm) Polydispersion Index (PI)
MNP − 38.72 ± 2.14 90.47 ± 2.88 0.337 ± 0.022
MNP–NGF − 1.59 ± 0.21 189.57 ± 5.91 0.328 ± 0.002
MNP–BDNF − 0.04 ± 0.03 273.07 ± 9.31 0.346 ± 0.009
 M. Giannaccini et al.
1 3
absent, even at the last time point (Fig. 1D3). Molecular 
analysis confirmed that the 14-day pre-incubated free NGF 
lost its ability to induce TrkA phosphorylation (p > 0.05), 
in sharp contrast to the 14-day pre-incubated conjugated 
Fig. 1  a RA-differentiated SH-SY5Y cells were incubated (5  days) 
with DMEM (A1) or DMEM modified with freshly frozen BDNF 
(100  ng/ml) (A2) or DMEM modified with freshly frozen MNP–
BDNF (100 ng/ml) (A3). b Increase in stability of BDNF following 
the conjugation to MNPs. DMEM modified with BDNF or MNP–
BDNF (100  ng/ml) was prepared. RA-differentiated SH-SY5Y cells 
were incubated (5 days) with the above-mentioned media freshly pre-
pared (DIV0) or pre-incubated at 4 °C for 3 days (DIV3) or pre-incu-
bated at 4 °C for 6 days (DIV6), and the percentage of interconnected 
neurites was calculated after fixation and staining. RA-differentiated 
SH-SY5Y cells were also incubated with BDNF-free DMEM as 
the control (not shown). n = 5, 2-way ANOVA followed by Bonfer-
roni correction (all groups compared against “DIV0”), p  <  0.0001. 
c Increase in stability of NGF following the conjugation to MNPs. 
Western blot analysis (p-TrkA 140 kDa and β-actin 42 kDa) carried 
out on extracts of PC12 cells, starved for 5 h in Optimem and treated 
for 5 min with the differentiation medium not modified (k), modified 
with NGF or MNP–NGF (100 ng/ml). Plots of p-TrkA band intensity 
normalized to β-actin band intensity. C1 WB analysis performed with 
freshly frozen NGF and MNP–NGF samples (DIV0). n  =  3, 1-way 
ANOVA followed by Bonferroni correction, p = 0.003. C2 WB anal-
ysis performed with NGF and MNP–NGF samples pre-incubated for 
2 weeks at 37 °C (DIV14). n = 3, 1-way ANOVA followed by Bon-
ferroni correction, p = 0.012. d NGF or MNP–NGF (100 ng/ml) were 
incubated at 37 °C from 0 to 3 weeks. Representative images of PC12 
cells treated with NGF (100 ng/ml) pre-incubated at 37 °C for 4 days 
(D1) or NGF 100 ng/ml pre-incubated at 37 °C for 14 days (D2) or 
MNP–NGF (100  ng/ml) pre-incubated at 37  °C for 14  days (D3). 
Other time points are shown in additional materials, Fig. S4
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NGF, which was still able to activate the receptor 
(p < 0.05) (Fig. 1C2).
Damage to GCL induced by oxidative stress
To induce retina damage, we IVT injected 2 nl (approxi-
mately 10% of larva vitreous volume) of  H2O2 (0.25–1 M) 
into 5 dpf larvae. First, we performed time course experi-
ments, to evaluate the time point corresponding to the 
maximum damage, following treatment with 2 nl of 1 M 
 H2O2. We analysed the damaged retina 2, 4, 8 and 24 hpi. 
We found that the population of TUNEL-positive cells rap-
idly increased in the first hours, until reaching a peak at 8 
hpi. The damage was partially restored 1 day after  H2O2 
injection because of the intrinsic regeneration capabilities 
of the developing larvae [31] (Fig. S5). Thus, all further 
experiments were performed by analysing the retina 8 h after 
damage induction.
Next, we performed dose–response experiments. We 
IVT injected 2 nl of 0.25, 0.5 and 1 M  H2O2 and the same 
volume of saline as the control experiment (k). We found 
a dose–response behaviour, with TUNEL-positive cells 
increasing in number with the hydrogen peroxide dosage. 
The quantitative analysis was performed by counting the 
fraction of TUNEL-positive cells in Ph, INL, GCL and 
CMZ. Results highlighted that the damage was especially 
localized at the level of GCL (Fig.  2). No statistically 
significant damage to photoreceptors, compared to the con-
trol, was observed at any concentration tested. A concentra-
tion of 0.25 M did not induce statistically significant damage 
in any cell layer. Conversely, concentrations of 0.5 M and 
1 M induced significant damage in INL, GCL and CMZ. In 
particular, the 1 M concentration, which induced cell apop-
tosis at 40.2 ± 5.2% levels in GCL, was considered a good 
model to validate the neuroprotective effects of the nanofor-
mulations developed in this study (Fig. 2).
Localization of IVT‑injected MNPs
Two nl (containing 10 or 20  ng) of MNPs were IVT 
injected into 4 dpf larvae. Localization was studied at 24 
hpi (Fig. 3a). Particles were found to localise in the retina, 
mainly distributed in the NR (Fig. 3B2) and RPE (Fig. 3B1), 
but a small fraction were also found in the choroid. Particles 
were never found in the controlateral eye or in other tissues 
(Fig. 3B3). As the surface coating is known to influence 
particle localization [22], we tested whether the NT con-
jugation altered the localization profile. Quantitative data 
analysis confirmed that MNP–NGF and MNP–BDNF had 
an identical localization profile of naked MNPs (p = 0.27), 
suggesting that NT conjugation or the dose do not change 
the fate of MNPs.
To study the localization kinetics of the conjugated 
MNPs, we used our previously published protocol, which 
Fig. 2  5 dpf larvae injected with 2 nl of various doses of  H2O2 and 
fixed 8 hpi. a–d TUNEL and Hoechst staining: representative sec-
tions of larvae injected with 0 (k), 0.25  M, 0.5  M or 1  M  H2O2. e 
Time course of the experiment. f Quantitative analysis of TUNEL-
positive cells in Ph, INL, GCL and CMZ cell layers for the differ-
ent doses. n ≥ 15 (embryos), 1-way ANOVA followed by Bonferroni 
correction (all groups compared against k group). Ph: p = 0.04. INL: 
p < 0.0001. GCL: p < 0.0001. CMZ: p = 0.0003
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consists in the fluorescent labelling of NGF with Alexa Fluor 
488 by a covalent approach  (NGFfluo) [24]. Figure 4 shows 
a section of 4 dpf larva injected with 2 nl of MNP–NGFfluo 
(16 ng MNPs, 0.5 ng  NGFfluo) at 6 hpi. MNPs (brown sig-
nal shown by red arrows, Fig. 4a) were found to co-localise 
with  NGFfluo (green fluorescence, Fig. 4b) in GCL and no 
fluorescence was detected in the vitreous. Our data thus sug-
gest that MNPs efficiently carry their protein load from the 
vitreous chamber toward the retina.
Conjugated NTs protect GCL from damage induced 
by oxidative stress
4 dpf larvae were IVT injected with free or conjugated pro-
tein and the damage was induced 16 h later by injecting 
 H2O2 (Fig. 5a). Larvae IVT injected with saline at 4 dpf and 
injected (16 h later) with  H2O2 or not injected, were used as 
the positive  (H2O2) and negative (k) controls, respectively. 
Figure 5 shows experimental data related to GCL and INL, 
where most of the damage induced by  H2O2 was observed 
(full data in Figs S6–8).
It has been reported that iron oxide MNPs may gener-
ate ROS through the Fenton and Haber–Weiss reactions 
[32]. In contrast, other studies have shown the capacity of 
MNPs to scavenge free radicals, thus attenuating oxidative 
damage induced by  H2O2 [33]. Therefore, we decided to 
first ascertain whether MNPs itself interfered with oxida-
tive stress in our model. We produced MNPs conjugated to 
BSA, which do not carry any neuroprotective stimulus, and 
injected 2 nl of dispersion into the vitreous (24 ng MNPs, 
1.8 ng BSA). The average fraction of TUNEL-positive 
RGCs was 0.008 ± 0.004 in the saline-treated group (k). 
The treatment with  H2O2 induced a significant increase in 
apoptosis, and the fraction of TUNEL-positive RGCs was 
0.484 ± 0.063 (p < 0.0001). The pre-treatment with MNP-
BSA had no effect, since the fraction of TUNEL-positive 
RGCs was 0.479 ± 0.069, i.e., not statistically different from 
the  H2O2-treated group (p > 0.05). Similarly, the MNP–BSA 
pre-treatment did not influence the apoptosis level in INL: 
the fraction of TUNEL-positive cells was 0.27 ± 0.033 and 
0.256 ± 0.024 in the  H2O2-treated and MNP–BSA-pre-
treated/H2O2-treated groups, respectively (not statistically 
different, p > 0.05), but were statistically different compared 
to k group (0.004 ± 0.003, p < 0.0001). We concluded that 
particles per se had a negligible effect on the apoptosis level.
Next, we tested the neuroprotection of the nanoformula-
tions developed here, using 0.5 ng of free and conjugated 
Fig. 3  Larvae (4 dpf) were injected with the nanoparticles, and 
localization was studied 24 hpi (a). Representative images of parti-
cles localized in RPE (B1) or in the NR (B2). Particles never localise 
outside the ocular tissues (B3). Particles are stained blue (Prussian 
blue). The bars are 100 µm. c Normalized distribution of MNP stain-
ing in the NR, RPE and the choroidal layer. n > 15, 2-way ANOVA, 
p = 0.27
Fig. 4  NGF was labeled with Alexa Fluor 488  (NGFfluo). MNP–
NGFfluo were injected into larvae (4 dpf) and the localization of 
MNPs and  NGFfluo was studied 6 hpi. MNPs (brown signal shown by 
red arrows in B1) and  NGFfluo (green staining in B2) were found to 
co-localise in the GCL
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NGF (Fig. 5c). We found that the IVT injection of free 
NGF did not prevent the damage induced by  H2O2 in 
GCL; the fraction of apoptotic cells was 0.504 ± 0.062 
and 0.406 ± 0.056 for the NGF-pre-treated/H2O2-treated 
and the  H2O2-treated groups, respectively (p > 0.05). In 
sharp contrast, the conjugated NGF totally prevented the 
 H2O2-induced damage because the apoptosis level in the 
MNP–NGF-pre-treated/H2O2-treated group (0.151 ± 0.044) 
was not statistically different from the control k group 
(0.005 ± 0.003) (p > 0.05). We also counted the number 
of RGCs and we found a decrease in the fraction of RGCs 
after the  H2O2-induced damage (0.78 ± 0.05, n > 15). The 
pre-treatment with the free protein reduced the RGC loss, 
however, the number of RGCs after damage induction 
was not statistically different from the  H2O2-treated group 
(0.911 ± 0.049, n > 15, p > 0.05). In line with previous data, 
the pre-treatment with the conjugated NGF totally prevented 
the RGC loss due to the oxidative stress (1.04 ± 0.053%, 
n > 15, p < 0.001).
A similar result was achieved in INL, where the apopto-
sis level caused by  H2O2 (0.215 ± 0.027) was not statisti-
cally different from the level found in the NGF-pre-treated/
H2O2-treated group (0.224 ± 0.035) (p > 0.05). On the other 
hand, the average number of TUNEL-positive cells in the 
MNP–NGF-pre-treated/H2O2-treated group (0.063 ± 0.019) 
was similar to the k group (0.003 ± 0.002) (p > 0.05).
In conclusion, we found clear evidence that the free NGF 
does not protect GCL and INL from the damage induced 
by  H2O2, in sharp contrast to the conjugated NGF. This is 
not surprising because the NGF dose used here was about 
10% of the dose (~ 0.4 μg NGF/μL of vitreous volume) usu-
ally required for effective neuroprotection of the retina from 
degeneration [34, 35]. Indeed, the conjugation of NGF to 
MNPs led to a drastic reduction in the dose required for 
neuroprotection.
Excellent results were also achieved by testing 2 ng of 
recombinant BDNF (Fig. 5d). RGC protection from dam-
age was achieved by the MNP–BDNF pre-treatment, with 
similar levels of TUNEL-positive cells to the control k 
(0.076 ± 0.039 and 0.005 ± 0.003 for BDNF-pre-treated/
H2O2-treated and k groups, respectively, p > 0.05), while the 
free protein had no effect (0.434 ± 0.051 and 0.453 ± 0.071 
for  H2O2-treated and BDNF-pre-treated/H2O2-treated 
groups, respectively, p > 0.05). Similarly, no significant 
apoptosis level was detected in INL in the group receiv-
ing the MNP–BDNF pre-treatment (0.042 ± 0.012 and 
0.003 ± 0.002 for BDNF-pre-treated/H2O2-treated and k 
groups, respectively, p > 0.05), while no neuroprotection 
Fig. 5  Larvae (4 dpf) were injected with the neuroprotective 
drug. Sixteen hours later, 2  nl of 1  M  H2O2 were injected and lar-
vae were fixed 8 h later (a). b Validation of control particles, which 
do not carry a neuroprotective drug (MNP-BSA). n  ≥  15, 1-way 
ANOVA followed by Bonferroni correction. INL: p  <  0.0001. 
GCL: p  <  0.0001. c Validation of particles, which carry 0.5  ng of 
NGF (MNP–NGF). n  ≥  15, one-way ANOVA followed by Bonfer-
roni correction. INL: p < 0.0001. GCL: p < 0.0001. d Validation of 
particles, which carry 2 ng of BDNF (MNP–BDNF). n ≥ 15, 1-way 
ANOVA followed by Bonferroni correction. INL: p < 0.0001. GCL: 
p < 0.0001. b–d Show pairs that are not statistically significant (ns)
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was actuated by the free protein (0.257  ±  0.03 and 
0.237  ±  0.035 for BDNF-pre-treated/H2O2-treated and 
 H2O2-treated groups, respectively, p > 0.05).
The visual behaviour of larvae was studied by examining 
the optokinetic response (OKR), i.e. larval eye movements 
(saccades) in response to rotating illuminated stripes, which 
can be accurately measured in developing larvae by 4 dpf 
[28]. The number of saccades per minute in non-injected 
larvae was 49.41 ± 2.57, which was not statistically dif-
ferent from the value of 54.12 ± 2.83 recorded in larvae 
IVT injected with 20 ng of MNPs (n > 35, p = 0.22), thus 
confirming the absence of optical toxicity arising from 
the MNPs (Fig. 6a). The injection of  H2O2 led to a loss of 
visual function (15.53 ± 1.70 saccades/min). No difference 
was found compared to the NGF-pre-treated/H2O2–treated 
groups (15.44  ±  2.64 saccades/min). However, a mod-
erate protection against visual loss was recorded for the 
MNP–NGF-pre-treated/H2O2-treated groups (25.24 ± 3.04), 
which reached statistical significance compared to the 
 H2O2-treated group (p < 0.05) and to the NGF-pre-treated/
H2O2-treated groups (p < 0.05) (Fig. 6b).
Discussion
This study tested the neuroprotective effect of NTs conju-
gated to MNPs versus the free factors. For the synthesis of 
MNP–BDNF, we covalently linked the protein to MNPs, 
according to a protocol we had already optimized for other 
growth factors such as GDNF [26] and the vascular endothe-
lial growth factor (VEGF) [22].
Compared to naked MNPs, the hydrodynamic size of 
MNP–BDNF tripled (Table 1). This increase probably 
depends on cross-linking events among two or a few 
particles rather than particle aggregation or precipita-
tion (the PI of MNP–BDNF and naked MNPs are similar, 
Table 1). This is a common mechanism already observed 
by performing the covalent synthesis of other proteins, 
such as BSA, GDNF [26] and VEGF [22]. In fact, pro-
teins have carboxylic groups that can be activated by EDC 
chemistry, leading to a degree of particle cross-linking, 
which is usually higher for covalent than for non-covalent 
chemistry [25]. For the synthesis of MNP–NGF, we used 
a non-covalent approach. In fact, in previous studies, we 
compared the physical load of NGF versus the chemical 
link of NGF to MNPs. Both strategies were very efficient 
for protein binding, leading to very stable conjugates, even 
after the addition of the cell growth medium [24], how-
ever, the chemical link impaired NGF bioactivity [26]. 
According to our evidence, physical binding should be the 
elective choice for NGF conjugation. Interestingly, this 
behaviour is protein-specific and cannot be generalized. 
For example, we observed that the chemical link of the 
GDNF to the MNPs totally preserved the protein bioac-
tivity, in sharp contrast to NGF [26]. Compared to naked 
MNPs, the hydrodynamic size of MNP–NGF doubled 
(Table 1). Similarly to MNP–BDNF, the cross-linking 
events among a few particles are probably responsible for 
such an increase (the PI of MNP–NGF decreased com-
pared to that of naked MNPs, Table 1). The presence of 
proteins on particle surfaces was confirmed by absorbance, 
Z potential (Table 1) and protein bioactivity measurements 
(Fig. 1).
In this study, we performed comparative biological stud-
ies on zebrafish larvae, whose retina were damaged by the 
oxidative stress induced by IVT injection of hydrogen per-
oxide. The reactive oxygen species (ROS) take part in the 
pathogenesis of anterior and posterior eye segment diseases 
in adults [36]. Superoxide is generated directly from a reduc-
tion in oxygen and then converted into hydrogen peroxide. 
 H2O2 can readily penetrate cell membranes and generate the 
most reactive form of oxygen, the hydroxyl radical. Low 
levels of ROS production are required for the physiologi-
cal control functions of the cells [37]. However, increased 
ROS production, oxidative retina damage and an imbalance 
between pro-oxidant and antioxidant capacities are believed 
to be crucial factors for glaucoma onset [38].
We used zebrafish embryos as a model system. Zebrafish 
have become a popular vertebrate model to study a variety 
of human diseases and are more recently becoming a valu-
able tool for the study of human ophthalmological disorders 
[39]. The visual system of the zebrafish is fundamentally 
similar to that of human subjects [40], and the layer of the 
Ph, INL, and GCL share the same structure as the human 
eye (Fig. S2). In contrast to humans, larval fish, frogs and 
birds have CMZ, which is located at the extreme periphery 
of the maturing neural retina and consists of retinal stem and 
Fig. 6  Optokinetic response assay. a Larvae were treated as shown 
in Fig. 3a. The injection of MNPs (20 ng) did not induce any change 
in OKR. n ≥ 35. T test, p = 0.22. b Larvae were treated as shown in 
Fig. 5a. The conjugated NGF but not the free NGF decreased visual 
function loss. n ≥ 30, one-way ANOVA followed by Bonferroni cor-
rection, p = 0.0095
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progenitor cells [41]. The retinal structure of fish starts to 
develop from 32 hpf (hours post fertilization) and is com-
plete within 5 dpf [42].
In this study, the damage was induced by intravitreally 
injecting 2 nl of 1 M  H2O2 in 5 dpf larvae. One of the dis-
advantages of using zebrafish to investigate ocular diseases 
affecting cell survival is the notable capacity for retinal cell 
regeneration, including the GCL [43]. We performed time-
course experiments to investigate the optimal time point 
for damage evaluation from the time of damage induction. 
We found that the apoptosis level quickly increased in the 
initial hours, reaching a peak at 8 hpi, followed by a reduc-
tion over time due to the intrinsic regeneration capability of 
the larvae (Fig. S5). After 8 hpi, we detected high levels of 
apoptosis in GCL (40.2 ± 5.61%), moderate levels in INL 
(21.5 ± 2.73%), low levels in CMZ (13.5 ± 2.63%) and neg-
ligible effects on the Ph layer (Fig. 2f). We then tested the 
potential of the nanoformulations developed in this study to 
prevent RGC damage induced by oxygen peroxide. Given 
the involvement of oxidative stress in the pathophysiology 
of glaucoma, neuroprotective or antioxidant therapies have 
been designed to prevent RGC loss and have been already 
tested pre-clinically [44]. Neuroprotective drugs should 
increase cellular resistance to the deleterious effects of oxi-
dative stress, while antioxidant drugs target the oxidative 
stress itself.
Ongoing studies are investigating the beneficial effects 
of antioxidants on glaucoma, such as α-tocopherol and 
Gingko (NCT01544192), or vitamin D in combination with 
memantine, an NMDA-receptor antagonist (NCT01409694), 
however, the therapeutic efficacy appears to be limited [44]. 
Despite the success of preclinical studies, clinical trials 
rarely test the neuroprotective effects of neurotrophic factors 
because of the difficulties with drug delivery. Here, we vali-
dated the neuroprotective effect of conjugated NTs, in com-
parison to free factors. Histological observations revealed 
that 0.5 ng of NGF 2.5S and 2 ng of recombinant BDNF 
conjugated to iron oxide MNPs induced total neuroprotec-
tion against RGC loss. The same amount of free factors had 
no effect on reducing the apoptosis level induced by ROS 
generation (Fig. 5). The conjugated NGF, but not the free 
protein, also attenuated the impairment of visual function 
caused by the IVT injection of  H2O2 (Fig. 6b).
We demonstrated that the conjugated MNPs actuated their 
neuroprotective action by combining two effects. First, the 
conjugation of the neurotrophic factors to MNPs increases 
their stability, preserves and thus improves their activity. Our 
data suggest that NTs conjugated to MNPs degrade more 
slowly than free NTs, and MNPs extend the half-life of NTs 
(Fig. 1). This result is consistent with data reported in the lit-
erature. Ziv-Polat and colleagues showed that NGF, GDNF 
or FGF-2 conjugated to iron oxide nanoparticles were sig-
nificantly more stable in cell cultures and in media than the 
free factors. This thus suggests that the coupling of proteins 
to nanoparticles prolongs their half-life and enhances their 
activity in vitro and in vivo, by protecting them against pro-
teolytic enzymes and inhibitors in the serum or secreted by 
the cells [45]. Similarly, Marcus and colleagues showed that 
NGF conjugated to iron oxide MNPs undergoes slower deg-
radation than free NGF, and conjugation improved the NGF 
function in inducing neuronal differentiation [46]. Here, we 
confirm that the conjugation of NTs to MNPs strongly pro-
longs NT biological activity over time.
Second, MNPs carry the neurotrophic factors in the retina, 
thus preventing their rapid mass loss due to physiological 
elimination. In a previous study, we demonstrated that iron 
oxide MNPs are able to self-accumulate in the retina [21]. 
Our previous results indicated that the MNPs progressively 
migrate from the vitreous chamber toward the retina, and 
that the migration process is completed within 24 h. Here, 
we demonstrated that MNPs transport their cargo (NTs) to 
GCL at 6 hpi (Fig. 4), progressively migrating toward the 
NR and the RPE, where they preferentially localise at 24 hpi 
(Fig. 3). In fact, MNPs can be used to maintain factors in situ 
and to prevent the loss of exogenously administered NTs 
over time due to physiological elimination, which naturally 
occurs in the vitreous.
Our studies have shown that the use of conjugated NTs 
could overcome the current limitations in terms of their ocu-
lar delivery, suggesting a therapeutically effective strategy 
for translating pre-clinically proven benefits into clinical 
applications. However, the anatomical and physiological 
differences between the zebrafish and human eye require 
further experimentation on mammalian models to extend 
the current results to other species, and to translate them 
into the clinical setting.
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